124 related articles for article (PubMed ID: 17942807)
1. The National Oncologic PET Registry (NOPR): design and analysis plan.
Hillner BE; Liu D; Coleman RE; Shields AF; Gareen IF; Hanna L; Stine SH; Siegel BA
J Nucl Med; 2007 Nov; 48(11):1901-8. PubMed ID: 17942807
[TBL] [Abstract][Full Text] [Related]
2. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Liu D; Shields AF; Gareen IF; Hanna L; Stine SH; Coleman RE
J Clin Oncol; 2008 May; 26(13):2155-61. PubMed ID: 18362365
[TBL] [Abstract][Full Text] [Related]
3. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.
Lindsay MJ; Siegel BA; Tunis SR; Hillner BE; Shields AF; Carey BP; Coleman RE
AJR Am J Roentgenol; 2007 Apr; 188(4):1109-13. PubMed ID: 17377055
[TBL] [Abstract][Full Text] [Related]
4. Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts.
Hillner BE; Siegel BA; Hanna L; Shields AF; Duan F; Gareen IF; Quinn B; Coleman RE
J Nucl Med; 2012 May; 53(5):831-7. PubMed ID: 22448033
[TBL] [Abstract][Full Text] [Related]
5. The National Oncologic PET Registry: lessons learned for coverage with evidence development.
Tunis S; Whicher D
J Am Coll Radiol; 2009 May; 6(5):360-5. PubMed ID: 19394577
[TBL] [Abstract][Full Text] [Related]
6. Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.
Hillner BE; Tosteson AN; Tosteson TD; Wang Q; Song Y; Hanna LG; Siegel BA
J Nucl Med; 2013 Dec; 54(12):2024-31. PubMed ID: 24221994
[TBL] [Abstract][Full Text] [Related]
7. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hunt E; Coleman RE
J Nucl Med; 2008 Dec; 49(12):1928-35. PubMed ID: 18997054
[TBL] [Abstract][Full Text] [Related]
8. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.
Hillner BE; Tosteson TD; Tosteson AN; Wang Q; Song Y; Onega T; Hanna LG; Siegel BA
Med Care; 2013 Apr; 51(4):361-7. PubMed ID: 23481033
[TBL] [Abstract][Full Text] [Related]
9. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Coleman RE
J Nucl Med; 2014 Apr; 55(4):574-81. PubMed ID: 24578240
[TBL] [Abstract][Full Text] [Related]
10. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
[TBL] [Abstract][Full Text] [Related]
11. Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Shields AF; Quinn B; Coleman RE
J Nucl Med; 2014 Jul; 55(7):1054-61. PubMed ID: 24819422
[TBL] [Abstract][Full Text] [Related]
12. Medicare coverage of PET for cervical cancer.
Carey BP; Coleman RE; Grigsby PW; Siegel BA
J Am Coll Radiol; 2006 Jan; 3(1):19-22. PubMed ID: 17412001
[TBL] [Abstract][Full Text] [Related]
13. Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry.
Hillner BE; Siegel BA; Shields AF; Duan F; Gareen IF; Hanna L; Coleman RE
Mol Imaging Biol; 2011 Feb; 13(1):161-5. PubMed ID: 21080232
[TBL] [Abstract][Full Text] [Related]
14. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
Hillner BE; Siegel BA; Shields AF; Liu D; Gareen IF; Hanna L; Stine SH; Coleman RE
Cancer; 2009 Jan; 115(2):410-8. PubMed ID: 19016303
[TBL] [Abstract][Full Text] [Related]
15. Hospice Admission and Survival After
Gareen IF; Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Siegel BA
J Nucl Med; 2018 Mar; 59(3):427-433. PubMed ID: 29284672
[TBL] [Abstract][Full Text] [Related]
16. Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany.
Pfannenberg C; Gueckel B; Wang L; Gatidis S; Olthof SC; Vach W; Reimold M; la Fougere C; Nikolaou K; Martus P
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):54-64. PubMed ID: 30269155
[TBL] [Abstract][Full Text] [Related]
17. Intended Versus Inferred Treatment After
Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
[TBL] [Abstract][Full Text] [Related]
18. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center.
Hillner BE; Tunuguntla R; Fratkin M
J Clin Oncol; 2004 Oct; 22(20):4147-56. PubMed ID: 15483025
[TBL] [Abstract][Full Text] [Related]
19. PET and PET/CT reports: observations from the National Oncologic PET Registry.
Coleman RE; Hillner BE; Shields AF; Duan F; Merlino DA; Hanna LG; Stine SH; Siegel BA
J Nucl Med; 2010 Jan; 51(1):158-63. PubMed ID: 20008997
[TBL] [Abstract][Full Text] [Related]
20. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
